Company Description
Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (“CNS”) disorders.
Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor associated proteins (“RAPs”), the latter of which play crucial roles in regulating receptor expression and function.
RAP-219, our most advanced product candidate, is designed to achieve neuroanatomical specificity through its selective targeting of a RAP known as TARPg8, which is associated with the neuronal AMPAR, a clinically validated target for epilepsy.
We completed our Phase 1 trials in healthy adults to assess the safety and tolerability of RAP-219, and we intend to initiate a Phase 2a proof-of-concept trial in adult patients with drug-resistant focal epilepsy in the second or third quarter of 2024, with topline results expected in mid 2025.
We believe RAP-219 also has therapeutic potential in peripheral neuropathic pain and bipolar disorder, and we intend to initiate Phase 2a trials in these indications in the second half of 2024 and in 2025, respectively.
We have also identified another TARPg8 targeted molecule with differentiated chemical and pharmacokinetic properties, RAP-199, for which we expect to initiate a Phase 1 trial in the first half of 2025.
| Country | United States |
| Founded | 2022 |
| IPO Date | Jun 7, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Abraham N. Ceesay, M.B.A. |
Contact Details
Address: 1325 Boylston Street, Suite 401 Boston, MA 02215 United States | |
| Phone | (857) 321-8020 |
| Website | rapportrx.com |
Stock Details
| Ticker Symbol | RAPP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0002012593 |
| Employer ID | 88-0724208 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Abraham N. Ceesay, M.B.A. | Chief Executive Officer and Director |
| Troy Ignelzi | Chief Financial Officer |
| David Bredt, M.D., Ph.D.(4) | Chief Scientific Officer and Director |
| Bradley S. Galer, M.D. | Chief Medical Officer |
| Cheryl Gault | Chief Operating Officer |
| Kathy Wilkinson | Chief People Officer |
| Swamy Yeleswaram, Ph.D. | Chief Development Officer |
| Steven M. Paul, M.D. | Director and Chairman |
| Terry-Ann Burrell, M.B.A. | Director |
| James I. Healy, M.D., Ph.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 24, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jun 21, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jun 20, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jun 14, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Jun 10, 2024 | 8-K | Current Report |
| Jun 7, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 7, 2024 | 424B4 | Prospectus |
| Jun 6, 2024 | EFFECT | Notice of Effectiveness |
| Jun 6, 2024 | CERT | Certification by an exchange approving securities for listing |
| Jun 4, 2024 | 8-A12B | Registration of securities |